This is Dimension 5 of 7 in the Patient Marketing Diligence Framework, a standard for evaluating whether a healthcare target’s patient acquisition is built to last or bought to look good for a sale.
Part 5 of 7 — The Patient Marketing Diligence (PMD) Framework
Most growth theses in healthcare M&A include some version of the same sentence: we’ll increase marketing spend after close.
It’s a reasonable plan, and it’s rarely tested. The model assumes that if $100K a month produces a certain number of patients, $200K a month produces roughly twice as many. Dimension 5 of the Patient Marketing Diligence framework, Scalability and Market Headroom, exists to check that assumption against the account’s actual data before the deal closes, because healthcare marketing scalability is almost never linear.
Headroom Versus Diminishing Returns
Every paid channel has a curve. Early spend captures the most efficient demand: the searches with the clearest intent, the audiences closest to booking. Each additional dollar reaches a slightly less eligible patient, so cost per patient rises as spend grows. That’s normal. What matters is where on the curve the target currently sits.
A target far down the curve has little headroom. It can spend more, but the incremental patients cost far more than the average CAC suggests, and the plan’s returns shrink with every added dollar. A target early on the curve has real room: the same market can absorb more spend at a similar efficiency. From the outside, the two can have identical headline numbers. The difference only shows up in the marginal cost, which is the cost of the next patient, not the average cost of all of them.
The Elasticity Test
The most useful evidence is a deliberate spend increase that already happened. If the target raised budget meaningfully at some point in the trailing 24 months, ask what happened to volume and cost per patient in the months that followed.
If spend rose 40% and patient volume rose roughly 40% at a similar cost, the curve is flat in that range and the growth plan has support. If spend rose 40% and volume rose 10%, the market was already close to saturation, and the post-close plan likely overstates what additional budget can buy.
Many targets have never run this test, because spend has been flat or only moved with seasonality. That’s not a failing, but it means the headroom is an assumption rather than a finding, and a buyer should price it as one.
Where to Look for Saturation Signals
In Google Ads, start with impression share, and split lost impression share into the part lost to budget and the part lost to rank. Share lost to budget means there’s demand the account isn’t reaching, which is a headroom signal. Share already high on the core terms, with little lost to budget, suggests the account is capturing most of the available search demand and extra spend will mostly pay for more expensive, lower-intent queries.
Auction Insights adds the competitive picture: who else is bidding on the same searches, and how often the target is outranked. Rising overlap from well-funded competitors, especially other PE-backed platforms, can push costs up for the target’s plan even if its own account is unchanged.
Then look at market size. Compare the target’s current patient volume to the addressable search demand for its core services in the markets it serves. Keyword volume tools give a rough ceiling, and it should be treated as a range, not a number. If the target already captures a large share of that range, the room to grow by spending is limited.
Why Market Density Changes the Answer
Headroom looks different by market. A dense, competitive metro with several large groups bidding on the same procedures saturates faster and gets more expensive at the margin. An underserved or newer market often has room, but usually less demand to begin with. A target’s growth plan should say which of these it’s counting on, and why.
Scoring It
The framework scores this dimension on evidence of real headroom, from clear evidence that comparable markets scale efficiently or that spend sits well below category norms at the top, down to documented saturation where past spend increases produced flat or declining volume at the bottom. A middle score of 3 is common: it means there isn’t enough historical spend variance to test the curve at all.
The Hard Flag is a documented spend increase that produced a proportionally smaller or negative volume response with no credible explanation. Soft Flags include no historical example of a deliberate spend test, and a market-size estimate that relies only on management’s own numbers.
Why It Matters for the Deal
This dimension tests whether the growth case is executable as modeled. If the plan calls for doubling marketing spend and the account is already near saturation, the same dollars buy far fewer patients than the model assumes, and the gap lands in EBITDA or in the timeline. Finding that out in diligence is a pricing conversation. Finding it out in month six is a miss against the plan.
This is Dimension 5 of 7 in the Patient Marketing Diligence Framework, a standard for evaluating whether a healthcare target’s patient acquisition is built to last or bought to look good for a sale.
Get the full framework: all 7 dimensions, complete scoring criteria, evidence sourcing, and red flag triggers, delivered free.
